Profile
| Metric | Value |
|---|---|
| Full Name | Madrigal Pharmaceuticals, Inc. |
| Ticker | NASDAQ: MDGL |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | madrigalpharma.com |
| Employees | 528 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $479.05 | |
| Price, 1D Change | +3.37% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.77 | |
| Revenue | $180M | |
| Revenue, 1Y Change | +100.00% | |
| EPS | -$21.90 | |
| EPS, 1Y Change | -9.54% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:35 | |
| Next Split | N/A | N/A |
| Last Ticker Change | SNTA | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$21.90 | |
| EPS Estimate | -$10.80 | |
| EPS Est. Change | +50.70% | |
| Revenue | $180.13M | |
| Revenue Estimate | $947.96M | |
| Revenue Est. Change | +426.26% | |
| Current Price | $479.05 | |
| Price Target | - | $638.00 |
| Price Tgt. Change | - | +33.18% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$19.48 | -$19.99 | -2.64% | |
| -$23.47 | -$21.90 | +6.69% | |
| -$10.80 | N/A | +50.70% | |
| $1.48 | N/A | +106.77% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| $174.49M | $180.13M | +3.23% | |
| $947.96M | N/A | +426.26% | |
| $1.46B | N/A | +712.73% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +45.05% | |
| Price, 3Y | +73.27% | |
| Market Cap, 1Y | +49.71% | |
| Market Cap, 3Y | +117.38% | |
| Revenue, 1Y | +100.00% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | -9.54% | |
| EPS, 3Y | -49.74% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $479.05 | |
| SMA 200 | $414.46 | |
| SMA 200 vs Price | -13.48% | |
| SMA 50 | $546.09 | |
| SMA 50 vs Price | +13.99% | |
| Beta | 0.77 | |
| ATR | $20.41 | |
| 14-Day RSI | 28.87 | |
| 10-Day Volatility | 32.48% | |
| 1-Year Volatility | 48.24% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $180.13M | |
| EPS | -$21.90 | |
| Gross Profit | $172.80M | |
| Gross Margin | 95.93% | |
| Operating Profit | -$497.88M | |
| Operating Margin | -276.39% | |
| Net Income | -$465.89M | |
| Net Margin | -258.64% | |
| EBITDA | -$450.13M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.16 | |
| 6.10 | ||
| 5.90 | ||
| - | ||
| 2 | ||
| 19.99 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 14.69 | ||
| 17.39 | ||
| -33.04 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $754.38M | |
| $931.25M | ||
| $1.04B | ||
| $1.03B | ||
| $287.86M | ||
| $169.28M | ||
| Total Debt | $119.57M | |
| $983.00K | ||
| $43.60M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $678.01M | ||
| $671.78M | ||
| $7.33M | ||
| $0.00 | ||
| $1.10M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$455.57M | ||
| -$274.39M | ||
| $735.06M | ||
| Capex | $6.46M | |
| -$462.03M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | ||
| Citizens | → | |
| Piper Sandler | → | |
| B. Riley Securities | → | |
| HC Wainwright & Co. | → | |
| Oppenheimer | → | |
| Truist Securities | → | |
| Canaccord Genuity | → | |
| HC Wainwright & Co. | → | |
| Citizens | → |
Analyst sentiment
Institutional ownership
Screeners with MDGL
FAQ
What is the ticker symbol for Madrigal Pharmaceuticals, Inc.?
The ticker symbol for Madrigal Pharmaceuticals, Inc. is NASDAQ:MDGL
Does Madrigal Pharmaceuticals, Inc. pay dividends?
No, Madrigal Pharmaceuticals, Inc. does not pay dividends
What sector is Madrigal Pharmaceuticals, Inc. in?
Madrigal Pharmaceuticals, Inc. is in the Healthcare sector
What industry is Madrigal Pharmaceuticals, Inc. in?
Madrigal Pharmaceuticals, Inc. is in the Biotechnology industry
What country is Madrigal Pharmaceuticals, Inc. based in?
Madrigal Pharmaceuticals, Inc. is headquartered in United States
When did Madrigal Pharmaceuticals, Inc. go public?
Madrigal Pharmaceuticals, Inc. initial public offering (IPO) was on February 6, 2007
Is Madrigal Pharmaceuticals, Inc. in the S&P 500?
No, Madrigal Pharmaceuticals, Inc. is not included in the S&P 500 index
Is Madrigal Pharmaceuticals, Inc. in the NASDAQ 100?
No, Madrigal Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is Madrigal Pharmaceuticals, Inc. in the Dow Jones?
No, Madrigal Pharmaceuticals, Inc. is not included in the Dow Jones index
When was Madrigal Pharmaceuticals, Inc. last earnings report?
Madrigal Pharmaceuticals, Inc.'s most recent earnings report was on November 4, 2025
When does Madrigal Pharmaceuticals, Inc. report earnings?
The next expected earnings date for Madrigal Pharmaceuticals, Inc. is February 19, 2026
Data Sources & References
- MDGL Official Website www.madrigalpharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1157601/000162828025048559/0001628280-25-048559-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1157601/000162828025007980/0001628280-25-007980-index.htm
- MDGL Profile on Yahoo Finance finance.yahoo.com/quote/MDGL
- MDGL Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/mdgl